IP Verse

Subcutaneously Administered Bispecific Antibodies For Use In The Treatment Of Cancer - EP3177645

The patent EP3177645 was granted to Lindhofer on Feb 17, 2021. The application was originally filed on Aug 10, 2015 under application number EP15756110A. The patent is currently recorded with a legal status of "Revoked".

EP3177645

LINDHOFER
Application Number
EP15756110A
Filing Date
Aug 10, 2015
Status
Revoked
Feb 16, 2024
Grant Date
Feb 17, 2021
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (11)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ABBVIENov 17, 2021MEWBURN ELLISADMISSIBLE
DR H ULRICH DORRIESNov 17, 2021DORRIESADMISSIBLE
DR H ULRICH DORRIESNov 17, 2021DORRIES, HANS ULRICH , DF-MP DORRIES FRANK-MOLNIA & POHLMANADMISSIBLE
GENMABNov 17, 2021J A KEMPADMISSIBLE
LAVA THERAPEUTICSNov 17, 2021COOLEY UKADMISSIBLE
MORPHOSYSNov 17, 2021SPILLERADMISSIBLE
BOEHRINGER INGELHEIM RCV BOEHRINGER INGELHEIMNov 16, 2021HOFFMANN EITLEADMISSIBLE
JAMES POOLENov 16, 2021CARPMAELS & RANSFORDADMISSIBLE
F HOFFMANN LA ROCHE GENENTECHNov 15, 2021MEWBURN ELLISADMISSIBLE
REGENERON PHARMACEUTICALSMay 26, 2021CARPMAELS & RANSFORDADMISSIBLE
JANSSEN BIOTECHMar 16, 2021CARPMAELS & RANSFORDWITHDRAWN

Patent Citations (44) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
EXAMINATIONUS2014050660
EXAMINATIONWO2014072277
INTERNATIONAL-SEARCH-REPORTWO2014028560
INTERNATIONAL-SEARCH-REPORTWO2014072277
OPPOSITIONCA2606081
OPPOSITIONEP1315520
OPPOSITIONEP1874821
OPPOSITIONEP2647707
OPPOSITIONUS2003223999
OPPOSITIONUS2006024300
OPPOSITIONUS2009191201
OPPOSITIONUS2010303827
OPPOSITIONUS2010322933
OPPOSITIONUS2012095192
OPPOSITIONUS2013309234
OPPOSITIONUS2014050660
OPPOSITIONUS2014088295
OPPOSITIONUS2014099254
OPPOSITIONUS2015335706
OPPOSITIONWO0220039
OPPOSITIONWO0230463
OPPOSITIONWO2004091658
OPPOSITIONWO2006089133
OPPOSITIONWO2006114115
OPPOSITIONWO2007093630
OPPOSITIONWO2009070642
OPPOSITIONWO2010037835
OPPOSITIONWO2010119119
OPPOSITIONWO2010151792
OPPOSITIONWO2011017330
OPPOSITIONWO2012064627
OPPOSITIONWO2012143524
OPPOSITIONWO2012151199
OPPOSITIONWO2012156430
OPPOSITIONWO2012162067
OPPOSITIONWO2014002183
OPPOSITIONWO2014028560
OPPOSITIONWO2014047231
OPPOSITIONWO2014072277
OPPOSITIONWO2014151910
OPPOSITIONWO2014167022
OPPOSITIONWO2015095392
OPPOSITIONWO2016019969
OPPOSITIONWO9704801

Non-Patent Literature (NPL) Citations (89) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
OPPOSITION- ALINARI, L. et al., "Alemtuzumab (Campath-1 H) in the treatment of chronic lymphocytic leukemia", Oncogene, (20070528), vol. 26, pages 3644 - 3653, XP055874529-
OPPOSITION- Anonymous, "CHMP assessment report Herceptin International non-proprietary name trastuzumab Procedure No. EMEA/ H/ C/ 000278", European Medicines Agency / EMA/CHMP/751770/2012/corr1, (20130627), pages 1 - 70, XP055858060-
OPPOSITION- Anonymous, "Subcutaneous Administration of Multispecific Antibody Makes Tumor Treatment Faster and More Tolerable", Press release HelmholtzZentrum muenchen, (20150701), pages 1 - 3, Press release HelmholtzZentrum muenchen, (20211126), XP055866480-
OPPOSITION- Aue Georg, Et Al, "Fractionated subcutaneous rituximab is well-tolerated and preserves CD20 expression on tumor cells in patients with chronic lymphocytic leukemia", Haematologica, (20100101), vol. 95, no. 2, pages 329 - 332, XP055878015-
OPPOSITION- Berger, Et Al., "Bioavailability of IgG Administered y the Subcutaneous Route", J. Clin. Immunol., (20130101), vol. 33, pages 984 - 990, XP055824091-
OPPOSITION- BILL STROHL, "Fine Tuning Therapeutic Antibodies as ''Fit-for- Purpose Biologics via Selection of Isotypes and Modified Fcs", Centocor, (20100224), XP055874530-
OPPOSITION- Brett S J, Et Al, "Differential functional effects of a humanized anti-CD4 antibody on resting and activated human T cells", Immunology, (19970101), vol. 91, pages 346 - 353, XP055868942-
OPPOSITION- Buhmann, R.; Stanglmaier, M.; Schuster, F.; Simoes, B.; Menzel, H.; Ruf, P.; Peschel, C.; Lindhofer, H.; Borkhardt, A.; Kolb, H. J.1, "Immunotherapy of recurrent B-cell malignancies in adult and paediatric patients with FBTA05, a trifunctional antibody (anti-CD3 X anti-CD20) and allogeneic donor lymphocyte infusion", Haematologica, Italy , (20100531), vol. 95, no. Suppl. 2, ISSN 1592-8721, page 183, XP009532314-
OPPOSITION- Dafne Muller, Kontermann, Roland, "Bispecific antibodies for cancer immunotherapy", Biodrugs, (20100101), vol. 24, no. 2, pages 89 - 98, XP055744248-
OPPOSITION- Dominique Leveque, "Subcutaneous Administration of Anticancer Agents", Anticancer Research, (20140401), vol. 34, pages 1579 - 1586, XP055344175-
OPPOSITION- EUROPEAN MEDICINES AGENCY, "ASSESSMENT REPORT FOR Removab; International Nonproprietary Name: catumaxomab; Procedure No. EMEA/H/C/000972", EMEA/CHMP/100434/2009, (20090219), URL: https://www.ema.europa.eu/en/documents/assessment-report/removab-epar-public-assessment-report_en.pdf, XP055871925-
OPPOSITION- Fuhrmann Stacy R, Et Al, "Abstract 5625: In Vitro and in Vivo pharmacology od MEDI-565 (MT111), a novel CEA/CD3-bispecific single-chain BiTE antibody in development for the treatment of gastrointestinal adenocarcinomas", Cancer Research, (20100401), vol. 70, no. 8 supp, pages 1 - 4, XP055866478-
OPPOSITION- Ismael Gustavo, Et Al, "Subcutaneous versus intravenous administration of (neo)adjuvant trastuzumab in patients with HER2-positive, clinical stage I-III breast cancer (HannaH study): a phase 3, open-label, multicentre, randomised trial ", Lancet, (20120901), vol. 13, pages 869 - 878, XP055878003-
OPPOSITION- KANEKO et al., Biodrugs, (20110000), vol. 25, no. 1, pages 1 - 11, XP002658156-
OPPOSITION- KIEWE et al., "Phase I Trial of the Trifunctional Anti-HER2 x Anti- CD 3 Antibody Ertumaxomab in Metastatic Breast Cancer", Clin Cancer Res, (20060515), vol. 12, no. 10, XP008067039-
OPPOSITION- KIEWE P, ET AL., "PHASE I TRIAL OF THE TRIFUNCTIONAL ANTI-HER2 X ANTI-CD3 ANTIBODY ERTUMAXOMAB IN METASTATIC BREAST CANCER", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20060515), vol. 12, no. 10, ISSN 0732-183X, pages 3085 - 3091, XP008067039-
OPPOSITION- KIEWE P, ET AL, "Phase I trial of the trifunctional anti-HER2 x anti-CD3 antibody ertumaxomab in metastatic breast cancer", PROGRAM/PROCEEDINGS - AMERICAN SOCIETY OF CLINICAL ONCOLOGY.ASCO, THE SOCIETY., US, US , (20050601), vol. 23, no. 16S, ISSN 1081-0641, page 2530, XP002391284-
OPPOSITION- Kontermann Roland E (ed.), "Bispecific Antibodies. Extracts.", Springer, (20110101), pages 1 - 20, XP055866476-
OPPOSITION- LINKE et al., mAbs, (20100000), vol. 2, no. 2, pages 129 - 136, XP055687390-
OPPOSITION- LORENCZEWSKI et al., "Experimental and Molecular Therapeutics", AACR Annual Meeting, XP009175471-
OPPOSITION- Negra George O, Et Al, "Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma", Haematologica, (20110101), vol. 96, no. 4, pages 567 - 573, XP055866867-
OPPOSITION- Negrea George O, Et Al, "Subcutaneous injections of low-dose veltuzumab (humanized anti-CD20 antibody) are safe and active in patients with indolent non-Hodgkin's lymphoma", Haematologica, (20110101), vol. 96, no. 4, pages 567 - 573, XP055866867-
OPPOSITION- Rathi Chetan, Et Al, "Clinical Pharmacology of Bispecific Antibody Constructs", The Journal of Clinical Pharmacology, (20150101), vol. 55, no. 53, pages 521 - 528, XP055868916-
OPPOSITION- Raza Afsheen, "Unleashing the immune response to NY-ESO-1 cancer testis antigen as a potential target for cancer immunotherapy", Journal Translational Medicine, (20200101), vol. 18, no. 140, pages 1 - 11, XP055868980-
OPPOSITION- Strohl William R, Strohl Lila M., "Therapeutic Antibody Engineering. Current and future advances driving the strongest growth area in the pharmaceutical Industry. Excerpts", Woodhead Publishing, (20120101), pages 1 - 14, XP055866482-
OPPOSITION- Thakur Archana; Lum Lawrence G, "Cancer therapy with bispecific antibodies: Clinical experience.", Current opinion in molecular therapeutics, (20100601), vol. 12, no. 3, ISSN 2040-3445, pages 340 - 349, XP009145639-
OPPOSITION- Ulrich H Weidle , Georg Tiefenthaler , Elisabeth H Weiss , Guy Georges , Ulrich Brinkmann, "The Intriguing Options of Multispecific Antibody Formats for Treatment of Cancer", CANCER GENOMICS & PROTEOMICS, (20130101), pages 1 - 18, XP055625711-
OPPOSITION- Wikipedia, "Arbovirus", (20210819), pages 1 - 8, URL: https://en.wikipedia.org/wiki/Arbovirus1, (20211203), XP055868958-
OPPOSITION- Wikipedia, "Fragment antigen-binding", (20210806), pages 1 - 3, URL: https://en.wikipedia.org/wiki/Fragment_antigen-binding, (20211203), XP055868920-
OPPOSITION- Wikipedia, "Hsp27", (20201230), pages 1 - 11, URL: https://en.wikipedia.org/wiki/Hsp27#Cellular_localization1, (20211203), XP055868928-
OPPOSITION- Wikipedia, "Hsp90", (20210902), pages 1 - 18, URL: https://en.wikipedia.Org/wiki/Hsp90#Cancerous_cells1, (20211203), XP055868931-
OPPOSITION- Wikipedia, "Human Leukocyte Antigen", (20211005), pages 1 - 12, URL: https://en.wikipedia.org/wiki/Human_leukocyte_antigen1, (20211203), XP055868959-
OPPOSITION- Wikipedia, "Melanoma-associated antigen", (20191020), pages 1 - 2, URL: https://en.wikipedia.org/wiki/Melanoma-associated_antigen1, (20211203), XP055868954-
OPPOSITION- Wikipedia, "P53", (20211008), pages 1 - 46, URL: https://en.wikipedia.org/wiki/P53#Function1, (20211203), XP055868963-
OPPOSITION- Wikipedia, "Survivin", (20210705), pages 1 - 22, URL: https://en.wikipedia.org/wiki/Survivin1, (20211203), XP055868983-
OPPOSITION- Wikipedia, "Telomerase", (20210922), pages 1 - 15, URL: https://en.wikipedia.org/wiki/Telomerase, (20211203), XP055868926-
OPPOSITION- Wikipedia, "Wikipedia entry: Pycard", (20210705), pages 1 - 11, URL: https://en.wikipedia.org/wiki/PYCARD1, (20211203), XP055868970-
OPPOSITION- Peter Ruf; Michael Jäger; Joachim Ellwart; Susanne Wosch; Elisabeth Kusterer; Horst Lindhofer, "Two new trifunctional antibodies for the therapy of human malignant melanoma", International Journal of Cancer, US , (20031113), vol. 108, no. 5, doi:10.1002/ijc.11630, ISSN 0020-7136, pages 725 - 732, XP071281617
OPPOSITION- "Therapeutic Interventions Targeting CD40L (CD154) and CD40: The Opportunities and Challenges", Che-Leung Law, Iqbal S. Grewal, Therapeutic Targets of the TNF Superfamily, New York, NY , Springer New York , (20090101), vol. 647, pages 8 - 36, doi:10.1007/978-0-387-89520-8_2, ISSN 00652598, ISBN 9780387895208, XP055096524
OPPOSITION- Launay-Vacher Vincent, "An appraisal of subcutaneous trastuzumab: a new formulation meeting clinical needs", Cancer chemotherapy and pharmacology, Springer Verlag , Berlin, DE, DE , (20130922), vol. 72, no. 6, doi:10.1007/s00280-013-2289-4, ISSN 0344-5704, pages 1361 - 1367, XP035339675
OPPOSITION- Hassan Abolhassani et al, "Home-Based Subcutaneous Immunoglobulin Versus Hospital-Based Intravenous Immunoglobulin in Treatment of Primary Antibody Deficiencies: Systematic Review and Meta Analysis", Journal of Clinical Immunology, Kluwer Academic Publishers-Plenum Publishers, Ne, Ne , (20120623), vol. 32, no. 6, doi:10.1007/s10875-012-9720-1, ISSN 1573-2592, pages 1180 - 1192, XP035153734
OPPOSITION- Varghese Abraham M., Rawstron Andy C., Hillmen Peter, "Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia: Should This Be the Goal of Treatment?", Current Hematologic Malignancy Reports, New York, (20100101), vol. 5, no. 1, doi:10.1007/s11899-009-0041-2, ISSN 1558-8211, pages 35 - 44, XP093101864
OPPOSITION- Spiess Christoph; Zhai Qianting; Carter Paul J., "Alternative molecular formats and therapeutic applications for bispecific antibodies", MOLECULAR IMMUNOLOGY, PERGAMON, GB, GB , (20150127), vol. 67, no. 2, doi:10.1016/j.molimm.2015.01.003, ISSN 0161-5890, pages 95 - 106, XP029246892
OPPOSITION- VAFA et al., Methods, (20140000), vol. 65, pages 114 - 126, XP002738919
OPPOSITION- Davies Andrew, Et Al, "Pharmacokinetics and safety of subcutaneous rituximab in follicular lymphoma (SABRINA): stage 1 analysis of a randomised phase 3 study", TheLancet, (20140210), vol. 15, pages 343 - 352, XP055857954
OPPOSITION- SHPILBERG O. & JACKISH C., "Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase", BRITISH J. CANCER, (20130903), vol. 109, doi:10.1038/bjc.2013.371, pages 1556 - 1561, XP002782443
OPPOSITION- R Buhmann, B Simoes, M Stanglmaier, T Yang, M Faltin, D Bund, H Lindhofer, H-J Kolb, "Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion", Bone Marrow Transplantation, Scientific & Medical Division, Macmillan Press, (20090301), vol. 43, no. 5, doi:10.1038/bmt.2008.323, ISSN 02683369, pages 383 - 397, XP055022699
OPPOSITION- R Buhmann et al, "Immunotherapy of recurrent B-cell malignancies after allo-SCT with Bi20 (FBTA05), a trifunctional anti-CD3 × anti-CD20 antibody and donor lymphocyte infusion", Bone Marrow Transplantation, (20090301), vol. 43, no. 5, doi:10.1038/bmt.2008.323, ISSN 02683369, pages 383 - 397, XP055022699
OPPOSITION- A. L. Bowen et al, "Subcutaneous CAMPATH‐1H in fludarabine‐resistant/relapsed chronic lymphocytic and B‐prolymphocytic leukaemia", British Journal of Haematology, John Wiley, Hoboken, USA, Hoboken, USA, (20031029), vol. 96, no. 3, doi:10.1046/j.1365-2141.1997.d01-2061.x, ISSN 0007-1048, pages 617 - 619, XP071102988
OPPOSITION- R Zeidler , J Mysliwietz, M Csánady, A Walz, I Ziegler, B Schmitt, B Wollenberg, H Lindhofer, "The Fc-region of a new class of intact bispecific antibody mediates activation of accessory cells and NK cells and induces direct phagocytosis of tumour cells", British Journal of Cancer, London, (20000701), vol. 83, no. 2, doi:10.1054/BJOC.2000.1237, ISSN 0007-0920, pages 261 - 266, XP002610993
OPPOSITION- C. Jackisch et al, "Subcutaneous Administration of Monoclonal Antibodies in Oncology", GEBURTSHILFE UND FRAUENHEILKUNDE, Georg Thieme Verlag, DE, DE , (20140428), vol. 74, no. 04, doi:10.1055/s-0034-1368173, ISSN 0016-5751, pages 343 - 349, XP055344155
OPPOSITION- C. Jackisch, Müller V., Maintz C., Hell S., Ataseven B., "Subcutaneous Administration of Monoclonal Antibodies in Oncology", GEBURTSHILFE UND FRAUENHEILKUNDE, Georg Thieme Verlag, DE, DE , (20140428), vol. 74, no. 04, doi:10.1055/s-0034-1368173, ISSN 0016-5751, pages 343 - 349, XP055344155
OPPOSITION- PECHE et al., Journal of Biological Chemistry, vol. 290, no. 49, pages 29652 - 29662, XP055845826
OPPOSITION- Ulrich Brinkmann, Roland E. Kontermann, "The making of bispecific antibodies", mAbs, US , (20170217), vol. 9, no. 2, doi:10.1080/19420862.2016.1268307, ISSN 1942-0862, pages 182 - 212, XP055531122
OPPOSITION- Datta-Mannan Amita, Estwick Selina, Zhou Chen, Choi Hiuwan, Douglass Nicole E., Witcher Derrick R., Lu Jirong, Beidler Catherine, Millican Rohn, "Influence of physiochemical properties on the subcutaneous absorption and bioavailability of monoclonal antibodies", mAbs, US , (20200101), vol. 12, no. 1, doi:10.1080/19420862.2020.1770028, ISSN 1942-0862, pages 1 - 14, XP093101840
OPPOSITION- BARGOU RALF ET AL, "Tumor regression in cancer patients by very low doses of a T cell-engaging antibody.", Science, American Association for the Advancement of Science, US, US , (20080815), vol. 321, no. 5891, doi:10.1126/SCIENCE.1158545, ISSN 0036-8075, pages 974 - 977, XP002615656
OPPOSITION- N. Deppisch et al, "Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20150801), vol. 14, no. 8, doi:10.1158/1535-7163.MCT-15-0156, ISSN 1535-7163, pages 1877 - 1883, XP055326304
OPPOSITION- N. Deppisch et al, "Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery", Molecular Cancer Therapeutics, US , (20150801), vol. 14, no. 8, doi:10.1158/1535-7163.MCT-15-0156, ISSN 1535-7163, pages 1877 - 1883, XP055326304
OPPOSITION- N. Deppisch, P. Ruf, N. Eissler, F. Neff, R. Buhmann, H. Lindhofer, R. Mocikat, "Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery", Molecular Cancer Therapeutics, American Association for Cancer Research, US, US , (20150801), vol. 14, no. 8, doi:10.1158/1535-7163.MCT-15-0156, ISSN 1535-7163, pages 1877 - 1883, XP055326304
OPPOSITION- N. Deppisch, P. Ruf, N. Eissler, F. Neff, R. Buhmann, H. Lindhofer, R. Mocikat, "Efficacy and Tolerability of a GD2-Directed Trifunctional Bispecific Antibody in a Preclinical Model: Subcutaneous Administration Is Superior to Intravenous Delivery", Molecular Cancer Therapeutics,, US , (20150801), vol. 14, no. 8, doi:10.1158/1535-7163.MCT-15-0156, ISSN 1535-7163, pages 1877 - 1883, XP055326304
OPPOSITION- Friedrich, "Abstract 3526: Subcutaneous administration of PSMA/CD3-bispecific BiTE antibody MT112/BAY 2010112 leads to complete remission of human prostate cancer xenografts in mice | Cancer Research", Cancer research, US , (20120415), vol. 72, no. 8 Supplement, doi:10.1158/1538-7445.AM2012-3526, ISSN 0008-5472, page 3526, XP055306961
OPPOSITION- WING, MG et al., "Mechanism of first-dose cytokine-release syndrome by CAMPATH 1-H: involvement of CD 16 (FcyRIII) and CD 11a/ CD 18 (LFA-1) on NK cel ls", J Clin Invest, (19961200), vol. 98, no. 12, pages 2819 - 2826, XP002559374
OPPOSITION- LUNDIN J, ET AL., "HEMATOLOGICAL RECOVERY AFTER ADMINISTRATION OF SUBCUTANEOUS ALEMTUZUMAB (MABCAMPATH) IN PREVIOUSLY UNTREATED VERSUS REFRACTORY B-CLL", Blood, American Society of Hematology, US, US , (20021116), vol. 100, no. 11, doi:10.1182/blood-2002-01-0159, ISSN 0006-4971, page 805A + ABSTR. NO. 3177, XP009040500
OPPOSITION- LUNDIN J., "Phase II trial subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)", Blood, American Society of Hematology, US, US , (20020101), vol. 100, doi:10.1182/blood-2002-01-0159, ISSN 0006-4971, pages 768 - 773, XP002987286
OPPOSITION- LUNDIN J., "Phase II trial subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL)", Blood, US , (20020101), vol. 100, doi:10.1182/blood-2002-01-0159, ISSN 0006-4971, pages 768 - 773, XP002987286
OPPOSITION- Pankaj Gupta et al, "Dual-targeting immunotherapy of lymphoma: potent cytotoxicity of anti-CD20/CD74 bispecific antibodies in mantle cell and other lymphomas.", Blood, US , (20120519), vol. 119, no. 16, doi:10.1182/BLOOD-2011-09-381988, ISSN 0006-4971, pages 3767 - 3778, XP002675543
OPPOSITION- Klinger Matthias, Brandl Christian, Zugmaier Gerhard, Hijazi Youssef, Bargou Ralf C., Topp Max S., Gökbuget Nicola, Neumann Svenja, Goebeler Mariele, Viardot Andreas, Stelljes Matthias, Brüggemann Monika, Hoelzer Dieter, Degenhard Evelyn, Nagorsen Dirk, Baeuerle Patrick A., Wolf Andreas, Kufer Peter, "Immunopharmacologic response of patients with B-lineage acute lymphoblastic leukemia to continuous infusion of T cell-engaging CD19/CD3-bispecific BiTE antibody blinatumomab", Blood, US , (20120628), vol. 119, no. 26, doi:10.1182/blood-2012-01-400515, ISSN 0006-4971, pages 6226 - 6233, XP093101874
OPPOSITION- RUF P, LINDHOFER H, "Induction of a long-lasting antitumor immunity by a trifunctional bispecific antibody.", Blood, US , (20011015), vol. 98, no. 8, doi:10.1182/blood.V98.8.2526, ISSN 0006-4971, pages 2526 - 2534, XP002660756
OPPOSITION- Peter Ruf;Beatrix Schäfer;Nina Eissler;Ralph Mocikat;Juergen Hess;Matthias Plöscher;Susanne Wosch;Ivonne Suckstorff;Christine Zehetmeier;Horst Lindhofer , "Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model", Journal of Translational Medicine, (20121107), vol. 10, no. 1, doi:10.1186/1479-5876-10-219, ISSN 1479-5876, page 219, XP021134191
OPPOSITION- Peter Ruf;Beatrix Schäfer;Nina Eissler;Ralph Mocikat;Juergen Hess;Matthias Plöscher;Susanne Wosch;Ivonne Suckstorff;Christine Zehetmeier;Horst Lindhofer , "Ganglioside GD2-specific trifunctional surrogate antibody Surek demonstrates therapeutic activity in a mouse melanoma model", Journal of Translational Medicine, BioMed Central, (20121107), vol. 10, no. 1, doi:10.1186/1479-5876-10-219, ISSN 1479-5876, page 219, XP021134191
OPPOSITION- Stilgenbauer Stephan, Et Al, "Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group", Journal of Clinical Oncology, American Society of Clinical Oncology, US, US , (20090820), vol. 27, no. 24, doi:10.1200/JCO.2008.21.1128, ISSN 0732-183X, pages 3994 - 4001, XP055877985
OPPOSITION- Zenjiro Sampei, Igawa Tomoyuki, Soeda Tetsuhiro, Okuyama Nishida Yukiko, Moriyama Chifumi, Wakabayashi Tetsuya, Tanaka Eriko, Muto Atsushi, Kojima Tetsuo, Kitazawa Takehisa, Yoshihashi Kazutaka, Harada Aya, Funaki Miho, Haraya Kenta, Tachibana Tatsuhiko, Suzuki Sachiyo, Esaki Keiko, Nabuchi Yoshiaki, Hattori Kunihiro, Lenting Peter, "Identification and Multidimensional Optimization of an Asymmetric Bispecific IgG Antibody Mimicking the Function of Factor VIII Cofactor Activity", PLoS ONE, Public Library of Science, US, US , (20130201), vol. 8, no. 2, doi:10.1371/journal.pone.0057479, ISSN 1932-6203, pages 1 - 13, XP055127871
OPPOSITION- WANG L et al., "Retargeting T Cells for HER2-Positive Tumor Killing by a Bispecific Fv-Fc Antibody", PLoS ONE, (20130923), vol. 8, no. 9, doi:10.1371/journal.pone.0075589, page e75589, XP055160755
OPPOSITION- Mao Cheng-Ping, Et Al, "Subcutaneous versus Intravenous Administration of Rituximab: Pharmacokinetics, CD20 Target Coverage and B-Cell Depletion in Cynomolgus Monkeys", PLoS ONE, (20131101), vol. 8, no. 11, doi:10.1371/journal.pone.0080533, page e80533, XP055877992
OPPOSITION- BUGELSKI et al., "Monoclonal antibody-induced cytokine-release syndrome", Expert Rev. Clin. Immunol., (20090000), vol. 5, no. 5, doi:10.1586/eci.09.31, pages 499 - 521, XP009184062
OPPOSITION- Bugelski Peter J; Achuthanandam Ram; Capocasale Renold J; Treacy George; Bouman-Thio Esther, "Monoclonal antibody-induced cytokine-release syndrome", Expert review of clinical immunology, England , (20090901), vol. 5, no. 5, doi:10.1586/eci.09.31, ISSN 1744-8409, pages 499 - 521, XP009184062
OPPOSITION- Bugelski Peter J; Achuthanandam Ram; Capocasale Renold J; Treacy George; Bouman-Thio Esther, "Monoclonal antibody-induced cytokine-release syndrome", Expert review of clinical immunology, England, England , (20090901), vol. 5, no. 5, doi:10.1586/eci.09.31, ISSN 1744-8409, pages 499 - 521, XP009184062
OPPOSITION- HAMIZI et al., "Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer", OncoTargets and Therapy, (20130213), vol. 6, doi:10.2147/OTT.S27733, pages 89 - 94, XP055476980
OPPOSITION- Salima Hamizi et al, "Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer", OncoTargets and Therapy, (20130213), vol. 6, doi:10.2147/OTT.S27733, pages 89 - 94, XP055476980
OPPOSITION- Salima Hamizi, Freyer Gilles; Bakrin Naoual; Henin Emilie; Mohtaram Amina; Le Saux Olivia; Falandry Claire, "Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer", OncoTargets and Therapy, (20130213), vol. 6, doi:10.2147/OTT.S27733, pages 89 - 94, XP055476980
OPPOSITION- Datta-Mannan Amita, Brown Robin, Key Stephanie, Cain Paul, Feng Yiqing, "Pharmacokinetic Developability and Disposition Profiles of Bispecific Antibodies: A Case Study with Two Molecules", Antibodies, (20220301), vol. 11, no. 1, doi:10.3390/antib11010002, pages 1 - 16, XP093101845
OPPOSITION- ROSENBERG SA, "IL -2: The First Effective Immunotherapy for Human Cancer", J Immunol, vol. 192, doi:10.4049/jimmunol.1490019, (20140606), pages 5451 - 5458, URL: https://www.jimmunol.org/content/192/12/5451/tab-article-info, XP055452257
OPPOSITION- Roy Jefferis, Marie-Paule Lefranc, "Human immunoglobulin allotypes", mAbs, Landes Bioscience, (20090101), vol. 1, no. 4, doi:10.4161/mabs.1.4.9122, pages 1 - 7, XP055096625
OPPOSITION- PATRICK CHAMES et al., "Bispecific antibodies for cancer therapy", mAbs, vol. 1, no. 6, doi:10.4161/mabs.1.6.10015, (20091101), pages 539 - 547, XP002688758
OPPOSITION- Chelius Dirk et al, "Structural and functional characterization of the trifunctional antibody catumaxomab.", mAbs, Landes Bioscience, US, US , (20100501), vol. 2, no. 3, doi:10.4161/mabs.2.3.11791, ISSN 1942-0870, pages 309 - 319, XP009137730
OPPOSITION- Rong Deng, Y. Gloria Meng, Kwame Hoyte, Jeff Lutman, Yanmei Lu, Suhasini Iyer, Laura E Deforge, Frank-Peter Theil, Paul J. Fielder, Saileta Prabhu, "Subcutaneous bioavailability of therapeutic antibodies as a function 
of FcRn binding affinity in mice", mAbs, US , (20120101), vol. 4, no. 1, doi:10.4161/mabs.4.1.18543, ISSN 1942-0862, pages 101 - 109, XP055646747
OPPOSITION- KONTERMANN ROLAND E, "Dual targeting strategies with bispecific antibodies", mAbs, Landes Bioscience, US, US , (20120301), vol. 4, no. 2, doi:10.4161/mabs.4.2.19000 , ISSN 1942-0862, pages 182 - 197, XP002698995
OPPOSITION- KONTERMANN ROLAND E, "Dual targeting strategies with bispecific antibodies", mAbs, US , (20120301), vol. 4, no. 2, doi:10.4161/mabs.4.2.19000 , ISSN 1942-0862, pages 182 - 197, XP002698995
OPPOSITION- Tapia-Galisteo Antonio, Compte Marta, Álvarez-Vallina Luis, Sanz Laura, "When three is not a crowd: trispecific antibodies for enhanced cancer immunotherapy", Theranostics, AU , (20230101), vol. 13, no. 3, doi:10.7150/thno.81494, ISSN 1838-7640, pages 1028 - 1041, XP093030659

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents